HiTide Biotechnology
Jiangsu HiTide Biotechnology Co., Ltd. (hereinafter referred to as "HiTide Biotechnology" or "Group") was founded in 2017 by Dr. Lin Xuye and his management team specializing in animal vaccine operations. It is a high-tech enterprise focused on the research and development, production, sales, and service of animal health products.
The company has gathered a group of senior technical backbones, including overseas returnee PhDs and senior experts, and has established deep cooperation with well-known universities and research institutes at home and abroad, mastering a series of new vaccine research and development platform technologies. The company has subsidiaries such as Haitaida Biotechnology (Guangzhou) Co., Ltd., Jiangxi Biomerit Biotechnology Co., Ltd., Shandong Haitaida Biotechnology Co., Ltd., Guangdong Haitaida Biotechnology Co., Ltd., and Guangzhou Xinqixing Biotechnology Co., Ltd. Its business covers multiple categories such as animal vaccines, antibodies, binding proteins, and pharmaceuticals for livestock, pets, and aquatic products.
At present, the company has 25 invention patents, 2 utility model patents, 15 new animal medicine certificates, over 200 production approvals, as well as 3 animal medicine GMP certificates, CNAS laboratory certification and other certificates.
In terms of team building, the research team led by Academician Jin Ningyi as the chief scientist mainly carries out product and technology research and development of biological products based on gene engineering expression, with strong market competitiveness and technological leadership. The founder of the company, Lin Xuye, holds a PhD in veterinary medicine from Southern Agricultural University. He has led research and development and has obtained multiple new veterinary drug certificates from the Ministry of Agriculture, including two Class I new veterinary drug certificates. Its ST swine fever vaccine technology has been transferred to 18 domestic production enterprises, with an initial transfer income of 144 million yuan. Dr. Lin Xuye has a keen insight into new products and technologies in biotechnology, and is able to seize industry opportunities in a timely manner. He makes accurate judgments on the company's product positioning, research and development direction, and selection of research and development varieties, winning development opportunities for the company. During his three consecutive terms as General Manager of Guangdong Yongshun Pharmaceutical Co., Ltd., he successfully promoted the company's listing on the main board, and this advantage will also be better reflected in HiTide Biotechnology.
In terms of research and development technology, the company has mastered subunit vaccine expression platform technologies such as baculovirus, Escherichia coli, yeast, as well as virus and cell bidirectional modification technologies, which can quickly study or construct vaccine strains for the research of new vaccines. For example, the pseudo rabies vaccine gene deletion vaccine modified by the company has a titer that is more than 1000 times higher than traditional vaccines. At present, the company has deep scientific research cooperation with domestic and foreign research institutes such as Cornell University, Oxford University, Sun Yat sen University, Nanjing Agricultural University, Yangzhou University, etc., and can fully integrate the most advanced animal vaccine research and production technology. Mr. Nais, former Belgian Ambassador to China, serves as the business consultant for our company, responsible for coordinating and integrating the urgently needed advanced biotechnology platforms in Europe and America.
At present, the antiviral binding protein developed by the company has applied for relevant patents and will be registered as a biological product for animal use by the Ministry of Agriculture in the future. At the same time, the company is also preparing research and production technology reserves for the future application of biological products for human use.
